Reprogramming is the
next leap forward in cancer immunotherapy

Direct Cell Reprogramming
Cancer Immunotherapy

Asgard Therapeutics

Asgard Therapeutics is a Swedish private biotech company exploring direct cell reprogramming technologies to develop ground-breaking cancer immunotherapies. Incorporated as a spin-off from Lund University, Asgard is pioneering gene therapy approaches with the proprietary lead program AT-108, designed to set in motion immune responses mediated by the biological properties of professional antigen presenting cells. Designed as an off-the-shelf gene therapy, Asgard´s approach overcomes many of the logistic and manufacturing hurdles of conventional cell-based therapies.

Read more
Co-founder and CEO Cristiana Pires explains the lead program AT-108 concept
Play video
Zoé Klein, André Rosa, Emilie Renaud, Xavier Catena, Iveta Mikalajūnaitė, Fritiof Åkerström, Xiaoli Huang, Fábio Rosa, Cristiana Pires, Filipe Pereira, Jan Villadsen

Our Team

Asgard Therapeutics brings together a growing team of experts in the cell reprogramming, gene therapy and immuno-oncology fields to guide our mission and develop pioneering off-the-shelf gene therapies based on the lead program AT-108.

Meet the members of our Executive Team and Board of Directors.

Read more